- Home
- Publications
- Publication Search
- Publication Details
Title
Ibrutinib: from bench side to clinical implications
Authors
Keywords
Ibrutinib, Bruton’s tyrosine kinase, Chronic lymphocytic leukemia, Follicular lymphoma, Mantle cell lymphoma, Non-Hodgkin lymphoma
Journal
MEDICAL ONCOLOGY
Volume 32, Issue 9, Pages -
Publisher
Springer Nature
Online
2015-07-29
DOI
10.1007/s12032-015-0669-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- The efficacy of ibrutinib in the treatment of Richter syndrome
- (2015) M. Tsang et al. BLOOD
- The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia
- (2015) Michael Hallek et al. Future Oncology
- Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
- (2015) Rossana Maffei et al. Journal of Hematology & Oncology
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bruton’s tyrosine kinase: oncotarget in myeloma
- (2015) Yu-Tzu Tai et al. Oncotarget
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib for the treatment of mantle cell lymphoma
- (2014) Nimish Shah et al. Expert Review of Hematology
- A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia
- (2013) G. Yang et al. BLOOD
- Molecular Pathways: Targeting the Microenvironment in Chronic Lymphocytic Leukemia—Focus on the B-Cell Receptor
- (2013) Elisa ten Hacken et al. CLINICAL CANCER RESEARCH
- Targeted Therapy in Chronic Lymphocytic Leukemia: Past, Present, and Future
- (2013) Alexey V. Danilov CLINICAL THERAPEUTICS
- Novel agents for chronic lymphocytic leukemia
- (2013) Mei Wu et al. Journal of Hematology & Oncology
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- (2013) Susan O'Brien et al. LANCET ONCOLOGY
- BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
- (2013) S Cheng et al. LEUKEMIA
- Ibrutinib in chronic lymphocytic leukemia and B cell malignancies
- (2013) Jennifer R. Brown LEUKEMIA & LYMPHOMA
- Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
- (2013) Munevver Cinar et al. LEUKEMIA RESEARCH
- Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- B cell receptor signaling in chronic lymphocytic leukemia
- (2013) Jan A. Burger et al. TRENDS IN IMMUNOLOGY
- Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
- (2012) Y.-T. Tai et al. BLOOD
- Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options
- (2012) Valentina Audrito et al. CANCER LETTERS
- BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB
- (2012) Stuart A. Rushworth et al. CELLULAR SIGNALLING
- Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies
- (2012) Adrian Wiestner JOURNAL OF CLINICAL ONCOLOGY
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
- (2012) Marcus Dühren-von Minden et al. NATURE
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- Regulation of BCR signaling
- (2011) Tomohiro Kurosaki MOLECULAR IMMUNOLOGY
- The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia
- (2010) Y. Herishanu et al. BLOOD
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Primary B Cell Immunodeficiencies: Comparisons and Contrasts
- (2009) Mary Ellen Conley et al. Annual Review of Immunology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now